WO2026109062 - PHARMACEUTICAL COMPOSITION CONTAINING ACYLATED INSULIN
National phase entry is expected:
Publication Number
WO/2026/109062
Publication Date
28.05.2026
International Application No.
PCT/CN2025/137614
International Filing Date
25.11.2025
Title **
[English]
PHARMACEUTICAL COMPOSITION CONTAINING ACYLATED INSULIN
[French]
COMPOSITION PHARMACEUTIQUE CONTENANT DE L'INSULINE ACYLÉE
[Chinese]
含酰化胰岛素的药物组合物
Applicants **
GAN & LEE PHARMACEUTICALS CO., LTD.
Inventors
BAO, Zhihao
YANG, Fengyun
ZHAO, Yifan
WANG, Zaiyu
WEN, Tingting
Priority Data
202411694480.6
25.11.2024
CN
202411694592.1
25.11.2024
CN
202510997777.8
19.07.2025
CN
202510997779.7
19.07.2025
CN
202511540595.4
27.10.2025
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2361 | |
| EPO | Filing, Examination, Granting | 16417 | |
| Japan | Filing, Examination, Granting | 2399 | |
| South Korea | Filing, Examination, Granting | 2799 | |
| USA | Filing, Examination, Granting | 8340 |
Total:
32,316
Contact Us
Abstract[English]
Provided are an acylated insulin preparation, a pharmaceutical composition of acylated insulin and a long-acting GLP-1 compound, and the medical use thereof. The preparation and the pharmaceutical composition have satisfactory physical stability, chemical stability, and safety.[French]
L'invention concerne une préparation d'insuline acylée, une composition pharmaceutique d'insuline acylée et un composé GLP-1 à action prolongée, et leur utilisation médicale. La préparation et la composition pharmaceutique présentent une stabilité physique, une stabilité chimique et une sécurité satisfaisantes.[Chinese]
提供一种酰化胰岛素制剂、酰化胰岛素与长效GLP-1化合物的药物组合物、及二者的医药用途。所述制剂和药物组合物具有令人满意的物理稳定性、化学稳定性、安全性。